Oramed Pharmaceuticals Inc. (NASDAQ:ORMP – Get Free Report) COO Joshua Hexter sold 137,000 shares of the stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $4.46, for a total transaction of $611,020.00. Following the completion of the sale, the chief operating officer owned 1,023,384 shares of the company’s stock, valued at approximately $4,564,292.64. This trade represents a 11.81% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.
Oramed Pharmaceuticals Stock Down 0.2%
Oramed Pharmaceuticals stock opened at $4.60 on Friday. Oramed Pharmaceuticals Inc. has a 52 week low of $1.98 and a 52 week high of $5.19. The company’s 50 day moving average price is $4.10 and its two-hundred day moving average price is $3.63. The stock has a market cap of $188.28 million, a P/E ratio of 1.78 and a beta of 1.21.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ORMP. SB Capital Management Inc purchased a new stake in shares of Oramed Pharmaceuticals during the 4th quarter worth approximately $5,415,000. Marshall Wace LLP purchased a new position in Oramed Pharmaceuticals in the fourth quarter valued at approximately $738,000. Dimensional Fund Advisors LP lifted its stake in Oramed Pharmaceuticals by 5.1% in the first quarter. Dimensional Fund Advisors LP now owns 158,209 shares of the biotechnology company’s stock valued at $538,000 after purchasing an additional 7,738 shares during the last quarter. Ritholtz Wealth Management bought a new position in Oramed Pharmaceuticals during the first quarter valued at $529,000. Finally, Bank of America Corp DE grew its holdings in Oramed Pharmaceuticals by 4.4% during the third quarter. Bank of America Corp DE now owns 149,667 shares of the biotechnology company’s stock valued at $395,000 after purchasing an additional 6,261 shares during the period. 12.73% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Ratings Changes
Get Our Latest Research Report on Oramed Pharmaceuticals
Oramed Pharmaceuticals Company Profile
Oramed Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of proprietary oral drug delivery systems, with an initial emphasis on diabetes management. Headquartered in Jerusalem, Israel, the company leverages its patented protein encapsulation technology, the “Oral Delivery Platform,” to transform injectable therapies into patient-friendly oral formulations. Oramed’s platform is designed to protect sensitive proteins and peptides from degradation in the gastrointestinal tract, enabling successful absorption and systemic delivery.
The company’s lead candidate, ORMD-0801, is an oral insulin capsule for patients with type 2 diabetes, currently advancing through Phase 3 clinical trials.
Featured Articles
- Five stocks we like better than Oramed Pharmaceuticals
- Shorting the Grid: Bloom Energy’s $25B AI Power Play
- SanDisk’s Volatility May Be Telling Bulls What They Want to Hear
- Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon
- 3 Dividend ETFs Built for Stability in a Volatile Market
Receive News & Ratings for Oramed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
